Just wondering what reception Vascepa is getting in the marketplace. Care to share your experience?
So...how's it going?
- Thread starter Anonymous
- Start date
-
- Tags
- None
It seems to be going well. The response has been quite receptive. I know no company or drug is perfect, but this seems to be a very easy company for which to work. It certainly has standards and strict guidelines but it isn't so rigid that you're not allowed to practice the selling techniques that Big Pharma has squashed. I'm not so dumb as to think this gig will last forever, but in this industry that is the new norm. You just keep plugging along and maintain a stellar professional reputation and hope for the best.
Great! Multiple conversions from L to the Big V. Also, many new starts for patients already on statins. V is going to be huge!
You must be the moron that is pumping the stock. This turd of a product is going to be a tough sell. There will not be conversions from one product to another. Instead, the hope is to get new patient starts, and it will still be tough.
Patients do just fine on Lovaza, so there really isn't a need to switch.
As yourself this: Why didn't some other large pharma company buy out Amarin? If this was really doing to be a big product, Amarin would have been acquired already.
While it is still early, it looks like this is going to be a tough sell.
Abbott and GSK trolls go away. WE are kicking your ass. By June you will see. Keep raising your price to offset your market share losses you losers.
There wasn't a prescription omega 3 on the market until Reliant. So that was a very good purchase.
You mean you look like an ass since sales are so low. Have trouble reading?
http://finance.yahoo.com/news/bulls-taking-another-shot-amarin-101402312.html
"Bulls taking another shot at Amarin
By David Russell (david.russell@optionmonster.com) | optionMONSTER – 4 hours ago
The bulls keep coming back to Amarin after a jarring selloff last year.
Once considered a takeover candidate, the drug maker gapped lower on Dec. 7 after announcing that it would market its Vascepa cholesterol drug without the benefit of a strategic partner. Management also borrowed at onerous rates to finance the effort.
Friday's option activity indicates that one big investor thinks AMRN is ready to recover all those losses, and then some. optionMONSTER's Heat Seeker scanner detected the purchase of 6,000 June 14 calls for $0.50 and the sale of an equal number of June 20 calls for $0.10. Volume was more than triple the previous open interest at each strike, indicating new positions.
Known as a bullish call spread , the strategy is highly leveraged to gains in the share price. It cost just $0.40 to open and will earn a profit of 1,400 percent if the stock closes at $20 or higher by expiration on June 21.
The relatively inexpensive cost of the trade is its main benefit, giving the investor exposure to a runaway rally while limiting risk in case the stock crashes. (See our Education section for more on how options can be safer than stocks.)
AMRN rose 0.59 percent to $8.58 on Friday. Calls outnumbered puts by a bullish 21-to-1 ratio. More than 20,000 contracts traded in total, compared with fewer than 9,000 in an average session."
"Bulls taking another shot at Amarin
By David Russell (david.russell@optionmonster.com) | optionMONSTER – 4 hours ago
The bulls keep coming back to Amarin after a jarring selloff last year.
Once considered a takeover candidate, the drug maker gapped lower on Dec. 7 after announcing that it would market its Vascepa cholesterol drug without the benefit of a strategic partner. Management also borrowed at onerous rates to finance the effort.
Friday's option activity indicates that one big investor thinks AMRN is ready to recover all those losses, and then some. optionMONSTER's Heat Seeker scanner detected the purchase of 6,000 June 14 calls for $0.50 and the sale of an equal number of June 20 calls for $0.10. Volume was more than triple the previous open interest at each strike, indicating new positions.
Known as a bullish call spread , the strategy is highly leveraged to gains in the share price. It cost just $0.40 to open and will earn a profit of 1,400 percent if the stock closes at $20 or higher by expiration on June 21.
The relatively inexpensive cost of the trade is its main benefit, giving the investor exposure to a runaway rally while limiting risk in case the stock crashes. (See our Education section for more on how options can be safer than stocks.)
AMRN rose 0.59 percent to $8.58 on Friday. Calls outnumbered puts by a bullish 21-to-1 ratio. More than 20,000 contracts traded in total, compared with fewer than 9,000 in an average session."
Oh you mean like KOS that held out for 4 years until they finally sold to Abbott? Mass $ made by employees. Everyone said they could not do it either.
Like taking cotton candy from a baby in carriage
You do know we can't say anything during a probation period nor even update a LinkedIn page, right? I will say, however, that life is GREAT. 
Much much better than I thought it might be! I WILl get internal medicine docs to switch! They see the value of not raising LDL.
Hey Glaxo trolls--- know what LDL is right? BAD ,,,,
Hey Glaxo trolls--- know what LDL is right? BAD ,,,,
The 1st week in field I had two big Lovaza Drs committ to switching to V. It will take a few weeks to start seeing them show up.
Oh, wow......that's big proof.......I am sure that thousands of investors will be buying up the stock today when the market opens.
By the way, did you notice the loud laughter coming from the room just after you walked out?